HerpDock: A GUI-based Gateway to HSV-1 Molecular Docking Insights

Overview

Journal Comput Struct Biotechnol J

Specialty Biotechnology

Date 2024 Nov 7

PMID 39507821

Authors

Sudhanshu Kumar Singh

Divya Kapoor

Deepak Shukla

Affiliations

Soon will be listed here.

Abstract

Herpes Simplex Virus 1 (HSV-1) is a member of the alpha-Herpesviridae family, with over 60 % of the global population being seropositive. HSV-1 can cause a range of symptoms, from mild discomfort to severe, life-threatening complications. The emergence of HSV-1-resistant strains and the diminishing effectiveness of current antiviral treatments highlight the urgent need for new antiviral drugs. Computational molecular docking studies can offer valuable insights for the development of novel antiviral compounds targeting HSV-1. To address this need, we have developed HerpDock, an open-source Graphical User Interface (GUI) program designed for molecular docking, high-throughput virtual screening, and absorption, distribution, metabolism, and elimination (ADME) studies. HerpDock stands out as a unique, user-friendly pipeline that extends beyond the capabilities of existing docking programs based on AutoDock Vina. It requires only the ligand name or structure from the user, as it already includes optimized structures of numerous HSV-1 viral proteins and relevant host proteins. With just a few clicks, HerpDock performs comprehensive docking studies, result analysis, and visualization, making it particularly valuable for Herpes researchers without a bioinformatics background. HerpDock is freely available at https://github.com/Sudhk24/Herpdock.

References

Patil C, Suryawanshi R, Kapoor D, Shukla D . Postinfection Metabolic Reprogramming of the Murine Trigeminal Ganglion Limits Herpes Simplex Virus-1 Replication. mBio. 2022; 13(5):e0219422. PMC: 9600155. DOI: 10.1128/mbio.02194-22. View

Wu J, Power H, Miranda-Saksena M, Valtchev P, Schindeler A, Cunningham A . Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D. Pharmaceuticals (Basel). 2022; 15(3). PMC: 8955139. DOI: 10.3390/ph15030361. View

Piperi E, Papadopoulou E, Georgaki M, Dovrat S, Bar Illan M, Nikitakis N . Management of oral herpes simplex virus infections: The problem of resistance. A narrative review. Oral Dis. 2023; 30(3):877-894. DOI: 10.1111/odi.14635. View

Sousa S, Ribeiro A, Coimbra J, Neves R, Martins S, Moorthy N . Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. Curr Med Chem. 2013; 20(18):2296-314. DOI: 10.2174/0929867311320180002. View

Patil C, Suryawanshi R, Ames J, Koganti R, Agelidis A, Kapoor D . Intrinsic Antiviral Activity of Optineurin Prevents Hyperproliferation of a Primary Herpes Simplex Virus Type 2 Infection. J Immunol. 2021; 208(1):63-73. PMC: 9015683. DOI: 10.4049/jimmunol.2100472. View

Baig M, Ahmad K, Rabbani G, Danishuddin M, Choi I . Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders. Curr Neuropharmacol. 2017; 16(6):740-748. PMC: 6080097. DOI: 10.2174/1570159X15666171016163510. View

Gaulton A, Bellis L, Bento A, Chambers J, Davies M, Hersey A . ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2011; 40(Database issue):D1100-7. PMC: 3245175. DOI: 10.1093/nar/gkr777. View

OBoyle N, Banck M, James C, Morley C, Vandermeersch T, Hutchison G . Open Babel: An open chemical toolbox. J Cheminform. 2011; 3:33. PMC: 3198950. DOI: 10.1186/1758-2946-3-33. View

Lazear E, Whitbeck J, Zuo Y, Carfi A, Cohen G, Eisenberg R . Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1. Virology. 2013; 448:185-95. PMC: 3979344. DOI: 10.1016/j.virol.2013.10.019. View

10.

Gagan S, Khapuinamai A, Kapoor D, Sharma P, Yadavalli T, Joseph J . Exploring Heparanase Levels in Tears: Insights From Herpes Simplex Virus-1 Keratitis Patients and Animal Studies. Invest Ophthalmol Vis Sci. 2024; 65(3):7. PMC: 10929742. DOI: 10.1167/iovs.65.3.7. View

11.

Gilbert C, Bestman-Smith J, Boivin G . Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 2002; 5(2):88-114. DOI: 10.1016/s1368-7646(02)00021-3. View

12.

Eberhardt J, Santos-Martins D, Tillack A, Forli S . AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021; 61(8):3891-3898. PMC: 10683950. DOI: 10.1021/acs.jcim.1c00203. View

13.

Canova P, Charron A, Leib D . Models of Herpes Simplex Virus Latency. Viruses. 2024; 16(5). PMC: 11125678. DOI: 10.3390/v16050747. View

14.

Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W . Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27(3):221-34. DOI: 10.1007/s10822-013-9644-8. View

15.

Cao S, Zhou M, Ji S, Ma D, Zhu S . Recent Advances in the Study of Alphaherpesvirus Latency and Reactivation: Novel Guidance for the Design of Herpesvirus Live Vector Vaccines. Pathogens. 2024; 13(9). PMC: 11435198. DOI: 10.3390/pathogens13090779. View

16.

Yadavalli T, Patil C, Sharma P, Volety I, Borase H, Kapoor D . Unique Attributes of Guinea Pigs as New Models to Study Ocular Herpes Pathophysiology and Recurrence. Invest Ophthalmol Vis Sci. 2023; 64(14):41. PMC: 10691389. DOI: 10.1167/iovs.64.14.41. View

17.

Madavaraju K, Koganti R, Volety I, Yadavalli T, Shukla D . Herpes Simplex Virus Cell Entry Mechanisms: An Update. Front Cell Infect Microbiol. 2021; 10:617578. PMC: 7848091. DOI: 10.3389/fcimb.2020.617578. View

18.

Kapoor D, Sharma P, Shukla D . Emerging drugs for the treatment of herpetic keratitis. Expert Opin Emerg Drugs. 2024; 29(2):113-126. DOI: 10.1080/14728214.2024.2339899. View

19.

Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang J . OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput. 2015; 12(1):281-96. DOI: 10.1021/acs.jctc.5b00864. View

20.

Rafiq H, Hu J, Hakami M, Hazazi A, Alamri M, Alkhatabi H . Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Sci Rep. 2023; 13(1):20147. PMC: 10656421. DOI: 10.1038/s41598-023-46193-x. View